Table 2.
Adjuvant therapy versus placebo.
| Pramipexole | Ropinirole | Pergolide∗ | Bromocriptine | Cabergoline | |
|---|---|---|---|---|---|
| Off-time reduction (h/day) | −1.81 | −0.93 | −1.60 | −1.78 | −1.29 |
| LEDD red (mg/day) | −114.82 | −119.81 | −183.90 | −52.17 | −149.60 |
| UPDRS ADL reduction (pts) | −1.78 | ||||
| UPDRS III reduction (pts) | −4.80 | −1.74 | |||
| Incidence of dyskinesia (OR) | 2.63 | 3.21 | 4.64 | 2.52 | 1.44 |
∗Based on data from just one trial [71].